The Theranostic Value of STARD3 in Colorectal Cancer: The STAR Study
ConditionColorectal Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCentro di Riferimento Oncologico - Aviano
About this trial
This study aims at verifying the overexpression of STARD3 in both early and advanced CRC patients derived tissues, to identify the pathways underpinning tumorigenesis and cancer progression in which STARD3 is involved. Moreover its role as a dynamic biomarker of treatment response and its part in treatment sensitivity will be explored.
Eligibility criteria
Qualifiers
Histologically confirmed diagnosis of colorectal cancer, independently from diagnosis stage.
Age ≥18 years.
Signed informed consent form.
Availability of tissue and blood samples stored at the Institutional Biobank for research purposes.
Disqualifiers
Patients for which the tumour biobanking process could compromise the diagnostic assessments.
Pregnancy or breast-feeding.
History of concomitant or previous malignancy in the previous 5 years, except for adequately treated cutaneous squamous cell carcinoma or surgically removed in situ cervical carcinoma.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov